Strategic Reviews, Liquidations, and Buybacks: Key Financial Developments in Biopharma, Real Estate
Kronos Bio (KRON) undergoes strategic review with 83% workforce reduction and CEO resignation, trading below net cash value.
Kronos Bio Strategic Review: Workforce Reduction, Leadership Changes, and Potential Sale Amid Genentech Partnership Uncertainty
Kronos Bio's NAV is estimated at $1.39/share, 48% above current price, with strategic review ongoing for sale/reverse merger.
278 Views
Kronos Bio IPO. Gilead’s SYK Inhibitor Portfolio Will Boost The Pipeline
A clinical-stage biotech company Kronos Bio, founded by partners and executives from Two River Group, priced its IPO of ~13.1 million shares at...
423 Views
No more insights